Message from the CEO

Fujirebio Group aims to develop and manufacture diagnostic products with new clinical value to the global market. Since our foundation in 1950 and the start of our diagnostic business in 1966, our focus has constantly been on innovation, stable supply and quality.

Today, as part of the H.U. Group, we prove the value of our new markers on our Lumipulse® and ESPLINE® platforms. Through various business models and broad partnerships, we aim to deliver our markers to the global community. Our R&D and manufacturing capabilities are located in Japan, Europe and US, working closely with our partners.

We value partnerships. Being considered as a trusted partner is key to our strategy. We are committed to fulfilling our responsibility in the global society through our business.

Goki Ishikawa, President & CEO of Fujirebio Holdings, Inc.

Veuillez confirmer que vous êtes un professionnel de la santé

Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

Choose your country or region

Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.